A photo of Sarangarajan Ranganathan.

Sarangarajan Ranganathan, MD


  • Endowed Chair and Division Director, Division of Pathology and Laboratory Medicine
  • Professor, UC Department of Pathology and Laboratory Medicine
I always approach each of my cases with the understanding that there is a patient and a family at the end of my microscope waiting for me to put a stamp on a child’s diagnosis that will start effective therapy.

About

Biography

The ability to contribute to the diagnosis and treatment of children is what propelled me into the field of pediatric pathology. My initial experiences in India made me realize how neglected children’s diseases are, and I wanted to change the situation in a small, personal way. That prompted me to get into pediatric pathology and hone my skills to provide the best possible service for the diagnosis of pediatric diseases.

There is a great need for pediatric pathologists as they form a very small group. Children are not “small adults”! They have a unique set of diseases that need to be recognized and treated if they are to be productive adults in the future.

I am the director of the Division of Pathology at Cincinnati Children’s. I’m involved in the diagnosis of all childhood diseases, and I have special expertise in the areas of solid tumors, liver diseases, kidney diseases and pediatric transplant pathology.

Pathologists are rarely seen at the forefront of patient care. They are always thought to be “someone who generated a report on my child’s illness that led to my physician successfully treating my child.” The role of the pathologist is not well known, but we are the only ones who can provide a definite diagnosis of your child’s illness, which guides your physician’s treatment process.

I always approach each of my cases with the understanding that there is a patient and a family at the end of my microscope waiting for me to put a stamp on a child’s diagnosis that will start effective therapy. This puts a big responsibility on our shoulders and helps us serve with humility and respect knowing that we are the final word.

As division chief of Pathology and Laboratory Medicine at Cincinnati Children’s, I am proud of the dedication and efforts of my colleagues who have stepped up to form an expert team. Our unique experiences and expertise enable us to project ourselves as one of the leading pediatric pathology divisions in the country. Our team works closely together to provide the correct diagnosis to patients every single time. Together, we do our best to offer the highest quality of care every day.

In addition to my clinical work, I’m also involved in research. My interest in pediatric tumors began in the late 1990s, and since then I have been able to advance my career to become an expert in the pathology of several tumors, including liver tumors and post-transplant tumors. My specific research focus is on the study of pediatric liver tumors including hepatoblastoma, a unique embryonal tumor of childhood, and pediatric hepatocellular carcinoma.

I am currently the reviewing pathologist for the Children’s Oncology Group study of liver tumors as part of an international collaboration. I have been studying the pathogenesis of liver tumors with special focus on the Wnt/beta-catenin pathway and its relationship to others, such as the Hippo pathway or interactions with other oncogenic proteins, such as EGFR. I have collaborated on several mouse models of liver tumors at the University of Pittsburgh and continue this work today. I have also studied the mechanisms of transplant rejection and cellular pathways in intestinal and liver transplant. I hope to contribute to the understanding of the pathogenesis of hepatoblastomas and pediatric hepatocellular carcinoma (HCC) and to identify potential biomarkers that can be used to predict outcomes in these rare tumors.

Since my move to Cincinnati, I have been immersed in my work and have not had time to look around. I hope to spend quality time with my family, go sightseeing, watch classic movies and listen to old songs.

Publications

Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. Sumazin, P; Peters, TL; Sarabia, SF; Kim, HR; Urbicain, M; Hollingsworth, EF; Alvarez, KR; Perez, CR; Pozza, A; Panah, MJ N; et al. Journal of Hepatology. 2022.

Pediatric Metastatic Hepatoblastoma With an ARID1A Mutation and Rhabdoid Cells. Alturkustani, M; Gallant, R; Raca, G; Ranganathan, S; Mahabir, R; Biegel, JA; Mascarenhas, L; Moke, D; Szymanski, LJ. International Journal of Surgical Pathology. 2022; 30:307-312.

A developmentally prometastatic niche to hepatoblastoma in neonatal liver mediated by the Cxcl1/Cxcr2 axis. Fan, L; Pan, Q; Yang, W; Koo, SC; Tian, C; Li, L; Lu, M; Brown, A; Ju, B; Easton, J; et al. Hepatology. 2022.

Coordinated Cross-Talk Between the Myc and Mlx Networks in Liver Regeneration and Neoplasia. Wang, H; Lu, J; Alencastro, F; Roberts, A; Fiedor, J; Carroll, P; Eisenman, RN; Ranganathan, S; Torbenson, M; Duncan, AW; et al. CMGH Cellular and Molecular Gastroenterology and Hepatology. 2022; 13:1785-1804.

Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study. Katzenstein, HM; Malogolowkin, MH; Krailo, MD; Piao, J; Towbin, AJ; McCarville, MB; Tiao, GM; Dunn, SP; Langham, MR; McGahren, ED; et al. Cancer. 2022; 128:1057-1065.

Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee. Trobaugh-Lotrario, A; Katzenstein, HM; Ranganathan, S; Lopez-Terrada, D; Krailo, MD; Piao, J; Chung, N; Randazzo, J; Malogolowkin, MH; Furman, WL; et al. Journal of Clinical Oncology. 2022; 40:459-467.

Late Allograft Fibrosis and Inflammation: An Unexpected Finding With Need for More Aggressive Treatment?. Ranganathan, S. Transplantation. 2022; 106:16-17.

Undifferentiated Embryonal Sarcoma of the Liver With Rhabdoid Morphology Mimicking Carcinoma: Expanding the Morphologic Spectrum or a Distinct Variant?. Papke, DJ; Fisch, AS; Ranganathan, S; O’Neill, A; Breen, M; Church, AJ; Perez-Atayde, AR; Al-Ibraheemi, A. Pediatric and Developmental Pathology. 2021; 24:564-569.

ALK-rearranged Renal Cell Carcinoma (RCC): A Report of 2 Cases and Review of the Literature Emphasizing the Distinction Between VCL-ALK and Non-VCL-ALK RCC. Wangsiricharoen, S; Zhong, M; Ranganathan, S; Matoso, A; Argani, P. International Journal of Surgical Pathology. 2021; 29:808-814.

Mutation Analysis and Disease Features at Presentation in a Multi-Center Cohort of Children With Monogenic Cholestasis. Hertel, PM; Bull, LN; Thompson, RJ; Goodrich, NP; Ye, W; Magee, JC; Squires, RH; Bass, LM; Heubi, JE; Kim, GE; et al. Journal of Pediatric Gastroenterology and Nutrition. 2021; 73:169-177.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey